0 CHECKOUT

Grass Pollen Allergy - Pipeline Review, H2 2015

  • ID: 3446780
  • September 2015
  • 62 pages
  • Global Markets Direct
1 of 3

Grass Pollen Allergy - Pipeline Review, H2 2015

Summary

The report ‘Grass Pollen Allergy - Pipeline Review, H2 2015’, provides an overview of the Grass Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Grass Pollen Allergy Overview

Therapeutics Development

Pipeline Products for Grass Pollen Allergy - Overview

Pipeline Products for Grass Pollen Allergy - Comparative Analysis

Grass Pollen Allergy - Therapeutics under Development by Companies

Grass Pollen Allergy - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Grass Pollen Allergy - Products under Development by Companies

Grass Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergy Therapeutics Plc

Anergis SA

Biomay AG

BioTech Tools s.a.

Circassia Pharmaceuticals Plc

HAL Allergy BV

Laboratorios LETI S.L.

Roxall Medizin GmbH

Shionogi & Co., Ltd.

Grass Pollen Allergy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AllerG - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen Extract for Grass Pollen Allergy, Asthma and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BM-32 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

clustoid wiesenlieschgras - Drug Profile

Product Description

Mechanism of Action

R&D Progress

gp-ASIT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-555739 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Timothy Grass Pollen Allergen Extract - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Grass Pollen Allergy - Recent Pipeline Updates

Grass Pollen Allergy - Dormant Projects

Grass Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.

Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32

Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK

Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study

Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32

Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK

Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet

Dec 06, 2013: Ethical committee of the University of Leuven approves a follow-up of the Phase IIa clinical study BTT006 to confirm a 2 years lasting immunological impact of 5 injections of gp-ASIT+TM

Nov 18, 2013: Update on Biotech Tools Phase IIa clinical study in the grass pollen allergy therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Grass Pollen Allergy, H2 2015

Number of Products under Development for Grass Pollen Allergy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2015

Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2015

Grass Pollen Allergy - Pipeline by Anergis SA, H2 2015

Grass Pollen Allergy - Pipeline by Biomay AG, H2 2015

Grass Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2015

Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015

Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2015

Grass Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2015

Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2015

Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2015

Grass Pollen Allergy - Dormant Projects, H2 2015

List of Figures

Number of Products under Development for Grass Pollen Allergy, H2 2015

Number of Products under Development for Grass Pollen Allergy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare